Magnesium deficiency increases ketamine sensitivity in rats

Canadian Journal of Anaesthesia

Volumn 44, Issue 8, 1997, Pages 883-890

  Orser, Beverley ^b,c   Smith, David ^a   Henderson, Sarah ^a   Gelb, Adrian ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ELECTROPHYSIOLOGY; HYPOMAGNESEMIA; IN VIVO STUDY; MAGNESIUM DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030721984     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03013166     Document Type: Article

References (47)

1. Walker GM. The roles of magnesium in biotechnology. Crit Rev Biotechnol 1994; 14: 311-54.
2. Narins RG. Maxwell and Kleeman's Clinical Disorders of Fluid and Electrolyte Metabolism, 5th ed. New York: McGraw Hill Inc, Health Professions Division, 1994.
3. Morris ME. Brain and CSF magnesium concentrations during magnesium deficit in animals and humans: neurological symptoms. Magnes Res 1992; 5: 303-13.
4. Whang R. Magnesium deficiency: pathogenesis, prevalence, and clinical implications Am J Med 1987; 82(Suppl 3A): 24-9.
5. Chutkow JG. Metabolism of magnesium in central nervous system. Neurology 1974; 24: 780-7.
6. Lerma A, Planells E, Aranda P, Llopis J. Evolution of Mg deficiency in rats. Ann Nutr Metab 1993; 37: 210-7.
7. Toffaletti J. Physiology and regulation. Ionized calcium, magnesium and lactate measurements in critical care settings. Am J Clin Pathol 1995; 104: S88-94.
8. Mori H, Mishina M. Review: Neurotransmitter receptors VIII. Structure and function of the NMDA receptor channel. Neuropharmacology 1995; 34: 1219-37.
9. Nowak, L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984; 307: 462-5.
10. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 1994; 330: 613-22.
11. MacDonald JF, Miljkovic Z, Pennefather P. Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Neurophysiol 1987; 58: 251-66.
12. MacDonald JF, Bartlett MC, Mody I, et al. Action of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol 1991; 432: 483-508.
13. Honey CR, Miljkovic Z, MacDonald JF. Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci Lett 1985; 61: 135-9.
14. Reich D, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989; 36: 186-97.
15. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl -asparate. Br J Pharmcol 1983; 79: 565-75.
16. Yamamura T, Harada K, Okamura A, Kemmotsu O. Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? Anesthesiology 1990; 72: 704-10.
17. Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M. Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. NeuroReport 1993; 4: 687-90.
18. 2+-block site of the NMDA receptor channel (Letter). Nature 1992; 358: 673-5.
19. Borchard RE, Barnes CD, Eltherington LG. Drug Dosage in Laboratory Animals. A Handbook, 3rd ed. Caldwell, New Jersey: The Telford Press Inc, 1990.
20. Petty C. Research Techniques in the Rat. Springfield, Illinois: Charles C. Thomas Publisher, 1982.
21. Smith W. Responses of laboratory animals to some injectable anaesthetics. Lab Anim 1993: 27; 30-9.
22. Tempelton DM, Paudyn A, Baines AD. Multielement analysis of biological samples by inductively coupled plasma-mass spectroscopy. Biol Trace Elem Res 1989; 22: 17-33.
23. Vaughan MA, Horlick G. Oxide, hydroxide, and doubly charged analyte species in inductively coupled plasma/mass spectrometry. Applied Spectroscopy 1986: 40; 434-45.
24. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981; 2: 93-113.
25. Cohen ML, Chan S-L, Way WL, Trevor AJ. Distribution in the brain and metabolism of ketamine in the rat after intravenous administration. Anesthesiology 1973; 39: 370-6.
26. Cohen ML, Trevor AJ. On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J Pharmacol Exp Ther 1974; 189: 351-8.
27. McIntyre I. An outline of magnesium metabolism in health and disease - a review. Journal of Chronic Diseases 1963: 16: 201-15.
28. Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-asparate receptors. Anesthesiology 1997; 86: 903-17.
29. Hartig P, Valtysson J, Lindner K-J, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995; 58: 165-73.
30. Irifune M, Shimizu T, Nomoto M, Fukuda T. Ketamine-induced anesthesia involves the N-methyl-D-aspartate receptor-channel complex in mice. Brain Res 1992; 596: 1-9.
31. White PF, Ham J, Way WL, Trevor AJ. Pharmacology of ketamine isomers in surgical patients. Anesthesiology 1980; 52: 231-9.
32. Zeilhofer HU, Swandulla D, Geisslinger G, Brune K. Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol 1992; 213: 155-8.
33. Douglas BG, Dagirmanjian R. The effects of magnesium deficiency on ketamine sleeping times in the rat. Br J Anaesth 1975; 47: 336-40.
34. Parsons CG, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995; 34: 1239-58.
35. 2+-deficient mice. Eur J Phamacol 1991; 204: 29-34.
36. Stone TW, Connick JH, Bartrup JT. NMDA-receptor-independent effects of low magnesium: involvement of adenosine. Brain Res 1990; 508: 333-6.
37. Chutkow JG, Tyce GM. Brain norepinephrine, dopamine, and 5-hydroxytryptamine in magnesium-deprivation encephalopathy in rats. J Neural Transm 1979; 44: 297-302.
38. Kantak KM. Magnesium deficiency alters aggressive behavior and catecholamine function. Behav Neurosci 1988; 102: 304-11.
39. Williams LT, Mullikin D, Lefkowitz, RJ. Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors. J Biol Chem 1978; 253: 2984-9.
40. Lefkowitz RJ, Mullikin D, Caron MG. Regulation of beta-adrenergic receptors by guanyl-5′-yl imidodiphosphate and other purine nucleotides. J Biol Chem 1976; 251: 4686-92.
41. Glossmann H, Hornung R, Presek P. The use of ligand binding for the characterisation of α-adrenoreceptors. J Cardiovasc Pharmacol 1980; 2: 303-24.
42. Wachtel RE, Wegrzynowicz ES. Kinetics of nicotinic acetylcholine ion channels in the presence of intravenous anaesthetics and induction agents. Br J Pharmacol 1992; 106: 623-7.
43. Wachtel RE. Ketamine decreases the open time of single-channel currents activated by acetylcholine. Anesthesiology 1988; 68: 563-70.
44. Scheller M, Bufler J, Schneck HJ, Franke C, Kochs E. Ketamine and its stereoisomers block the nicotinic acetylcholine receptor of mouse myotubes. Anesth Analg 1996; 82: S396.
45. Durieux ME. Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg 1995; 81: 57-62.
46. Zaloga G. Magnesium, anesthesia, and hemodynamic control (Editorial). Anesthesiology 1991; 74: 1-2.
47. Loeb WF, Quimby FW. The Clinical Chemistry of Laboratory Animals. Pergamon Press, 1989: 417-76.